Product Description: Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5)[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071./[2]Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78(13_Supplement): LB-295-LB-295.
CAS Number: 2245205-37-0
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
